Results 121 to 130 of about 87,366 (344)

Genetic attenuation of ALDH1A1 increases metastatic potential and aggressiveness in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Aldehyde dehydrogenase 1A1 (ALDH1A1) is a cancer stem cell marker in several malignancies. We established a novel epithelial cell line from rectal adenocarcinoma with unique overexpression of this enzyme. Genetic attenuation of ALDH1A1 led to increased invasive capacity and metastatic potential, the inhibition of proliferation activity, and ultimately ...
Martina Poturnajova   +25 more
wiley   +1 more source

Serum Phosphorus and Pill Burden Among Hemodialysis Patients Prescribed Sucroferric Oxyhydroxide: One-Year Follow-Up on a Contemporary Cohort

open access: yesInternational Journal of Nephrology and Renovascular Disease, 2022
Jessica B Kendrick,1 Meijiao Zhou,2 Linda H Ficociello,2 Vidhya Parameswaran,2 Claudy Mullon,2 Michael S Anger,2,3 Daniel W Coyne4 1University of Colorado Anschutz Medical Campus, Aurora, CO, USA; 2Fresenius Medical Care Global Medical Office, Waltham ...
Kendrick JB   +6 more
doaj  

Production of phosphate binder fire-protective coating for steel building constructions [PDF]

open access: yes, 2012
Brief analysis of means for fire protection of steel building constructions was given, special attention being paid to the advantages of using phosphate binders for protective coatings.
Kuzmenkov, M. I., Rumynskaya, E. I.
core  

Dimethyl fumarate combined with cisplatin at subcytotoxic doses sensitizes cervical cancer toward ferroptosis and apoptosis through GSH restriction and p53 (re)activation

open access: yesMolecular Oncology, EarlyView.
Dimethyl fumarate (DMF) reduces growth of HPV‐positive cervical cancer spheroids and induces ferroptosis in cervical cancer cells via blocking SLC7A11/Glutathione (GSH) axis. Combination of subcytotoxic doses of DMF and cisplatin (CDDP) further suppresses spheroid growth and drives cell death in 2D culture models.
Carolina Punziano   +6 more
wiley   +1 more source

Serum phosphate level at initiation of dialysis is associated with all-cause mortality: a multicenter prospective cohort study

open access: yesRenal Failure, 2018
Introduction: As glomerular filtration rate (GFR) decreases, serum phosphate level increases. Previous reports indicated that serum phosphate level was associated with mortality in patients on dialysis.
Akiko Owaki   +10 more
doaj   +1 more source

Intact FGF23 predicts serum phosphate improvement after combined nicotinamide and phosphate binder treatment in hemodialysis patients. [PDF]

open access: yesClin Kidney J, 2023
Egli-Spichtig D   +12 more
europepmc   +1 more source

Targeted modulation of IGFL2‐AS1 reveals its translational potential in cervical adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
Cervical adenocarcinoma patients face worse outcomes than squamous cell carcinoma counterparts despite similar treatment. The identification of IGFL2‐AS1's differential expression provides a molecular basis for distinguishing these histotypes, paving the way for personalized therapies and improved survival in vulnerable populations globally.
Ricardo Cesar Cintra   +6 more
wiley   +1 more source

Safety and Phosphate‐Binding Capacity of Oxylanthanum Carbonate in Healthy Volunteers

open access: yesClinical and Translational Science
Despite the widespread use of currently available serum phosphate management options, elevated serum phosphate is common in patients with end‐stage kidney disease on dialysis.
Pablo E. Pergola   +7 more
doaj   +1 more source

Effect of Tenapanor on Phosphate Binder Pill Burden in Hemodialysis Patients. [PDF]

open access: yesKidney Int Rep, 2021
Akizawa T   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy